Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin allowance compared to placebo and to etanercept at the 12-week endpoint. Epidermis leeway was studied via mean peerless endpoints looking for psoriasis studies: the Psoriasis Field and Pitilessness Index (PASI) and the Stagnant Physician Broad Assessment (sPGA).
Representing patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI groove (PASI 75) at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. Destined for similarity, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100.
Statistically meritorious improvements in husk hole measures after patients treated with ixekizumab were observed as cock's-crow as the oldest week when compared to either placebo or etanercept, and continued in every way week 12. In the UNCOVER-1 learning, squiffed levels of response were maintained from top to bottom 60 weeks of treatment.